Alerta

USE OF ANTI-CD20 ANTIBODY DRUG CONJUGATE IN PREPARATION OF DRUG FOR TREATING NON-HODGKIN LYMPHOMA

Resumen de: US20260241027A1

0000 The present disclosure discloses a use of anti-CD20 ADC in the preparation of a drug for treating NHL, and the drug has excellent clinical efficacy and safety in treating a R/R NHL patient after receiving at least two standard treatments.

CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING FL1-1 EXPRESSION

Resumen de: US20260241033A1

The present disclosure is directed to CRISPR-related systems and components for targeting, editing, and/or modulating expression of a FLI-1 (Friend virus leukemia integration 1 transcription factor; Fli-1 Proto-Oncogene, ETS Transcription Factor) gene. The present disclosure also relates to methods and applications thereof in connection with engineered cells including T cells or T cell precursors.

COMPOSITIONS FOR TREATMENT OF CANCER AND USES THEREOF

Resumen de: WO2026174057A1

The present disclosure provides for compositions comprising a combination of marine biomass extracts for use in the treatment of cancer, where the cancer is a leukemia, a bladder cancer, a gastric cancer, a breast cancer, a multiple myeloma, a lung cancer, or a pancreatic cancer. Further provided herein are biomass compositions having extracts from Holothuria scabra, Holothuria nobilis, Heliocidaris erythrogramma, Styela clava, and Sargassum pallidum. Moreover, in such compositions the majority components may be extracts from sea cucumber.

Compounds

Resumen de: GB2704112A

A compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, is provided, wherein R groups are as defined herein, X-Y is -NHSO2-, A is selected from: a C4-C8-cycloalkyl group; a bicyclic C5-C12-cycloalkyl group; and a C4-C8-cycloalkyl group fused to an aryl or heteroaryl group; each of which is optionally substituted by one or more R4 groups; R1 is haloalkyl or OR3; R2 is H or halo; R3 is alkyl or benzyl; and each R4 is independently alkyl or halo. B is NR6R7, wherein R6 and R7 are linked to form a polycyclic group containing at least one spiro carbon, and which polycyclic group optionally contains one or more groups independently selected from NR35, CO, O, S, SO and SO2, and is optionally further substituted by one or more R5 groups; each R5 is independently selected from COOH, CONR8R9, CONHSO2R10, NR30R31, CO2-alkyl, OH, alkyl, halo, haloalkyl, alkoxy, aminoalkyl, and hydroxyalkyl. The compounds modulate ERAP2 and are useful in treating proliferative, viral, immune or inflammatory disorders, particularly cancer or leukaemia. The compounds stimulate a neo-antigen directed immune response. Methods of producing antigen-presenting cells and immunogenic compositions are also disclosed. Exemplified compounds include N-(2-(cyclohexylamino)-5-(trifluoromethyl)phenyl)-2,4-dioxo-1,3,7-triazaspiro4,5decane-7-sulfonamide No Figure

METHODS FOR PREDICTING RESPONSIVENESS OF LYMPHOMA TO DRUG AND METHODS FOR TREATING LYMPHOMA

Resumen de: WO2025080543A1

Provided herein are methods of predicting the responsiveness of a lymphoma patient to a cancer treatment. Also provided herein are methods of treating a lymphoma patient based on predicting the responsiveness of the lymphoma patient to a cancer treatment.

METHODS FOR TREATING MULTIPLE MYELOMA COMPRISING AN ANTI-CD38 ANTIBODY COMBINED WITH BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE

Resumen de: WO2025080911A1

The present disclosure is directed to methods of treating multiple myeloma. The present disclosure is directed to methods of treating newly diagnosed multiple myeloma in a subject in need thereof, for example, by subcutaneously administering to the subject a pharmaceutical composition comprising an anti-CD38 antibody in combination with bortezomib, lenalidomide, and dexamethasone.

ANTI-VISTA ANTIBODIES AND FRAGMENTS

Resumen de: US20260234264A1

The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.

ANTI-CD180 BINDING MOLECULES AND USES THEREOF

Resumen de: US20260232824A1

0000 The present disclosure provides anti-CD180 binding molecules and uses thereof. In one embodiment, the anti-CD180 binding molecules are anti-CD180 antibodies. Also provided are anti-CD180 antibody-drug conjugates (ADCs) comprising a CD180-high expressing tumor-targeting monoclonal antibody or antigen-binding fragment thereof, a cytotoxic drug payload and a linker moiety conjugating the CD180-high expressing tumor-targeting antibody or the antigen-binding fragment thereof to the cytotoxic drug payload. The anti-CD180 antibodies or the antigen binding fragments thereof, and the ADCs comprising the anti-CD180 antibodies, or the antigen binding fragments thereof are useful in treating diseases, such as acute myeloid leukemia, mantle cell lymphoma, multiple myeloma. follicular lymphoma, B-acute lymphoblastic leukemia, or diffuse large B-cell lymphoma.

Use of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) in Rare Anemia

Resumen de: US20260234146A1

The present application relates to use of a hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHI) in rare anemia. Specifically disclosed in the present application is use of certain hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) in the treatment of anemia of myelodysplastic syndromes (MDS anemia), beta-thalassemia (β-thalassemia), and/or sickle cell disease (sickle cell anemia, SCD anemia).

COMPOUNDS FOR TREATING BRAIN CANCER

Resumen de: US20260232638A1

0000 There is provided a compound of formula I or a pharmacologically acceptable salt thereof: 0000 for use in the treatment of a brain cancer selected from a MGMT positive astrocytic brain tumor, a metastatic brain cancer and primary CNS lymphoma and a method of treating said brain cancers in a patient in need thereof comprising administering to the patient said compound of formula I or a pharmacologically acceptable salt thereof.

THERAPY FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA

Resumen de: US20260232683A1

0000 Provided herein are methods of treating and/or managing non-Hodgkin lymphoma, which comprise administering to a patient 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (“Compound A, A-S, or A-R”), or an enantiomer or mixture of enantiomers, a tautomer, an isotopolog, a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in combination with glofitamab or mosunetuzumab.

NOVEL IMIDAZOLE DERIVATIVE AND USE THEREOF

Resumen de: US20260234129A1

The present invention relates to a novel imidazole derivative and a pharmaceutical composition for treating protein kinase-associated diseases, comprising same as an active ingredient. More specifically, the present invention relates to a novel imidazole derivative and a pharmaceutical composition comprising same as an active ingredient, the derivative inhibiting protein kinase activity so as to prevent or treat cancer diseases. In addition, the compound and the pharmaceutical composition, comprising same as an active ingredient, of the present invention, effectively inhibit FLT3 kinase activity, and thus can be effectively used for preventing or treating mutant FLT3-associated diseases, particularly acute myeloid leukemia.

SUPER RESOLUTION MICROSCOPIC IMAGING OF T LYMPHOCYTE CLONALITY COMBINING MULTIPLEXED SEQUENTIAL FLUORESCENCE IN SITU HYBRIDIZATION WITH BULK GENOMIC DNA SEQUENCING

Resumen de: WO2026170226A1

This disclosure provides methods for imaging of samples for diagnosis of lymphoid neoplasms, lymphocytic autoimmune disease, and other conditions related to clonal expansion of lymphocytes. Using these methods, individual lymphocytes can be imaged in situ to determine tissue-wide clonality based on rearrangement of T cell receptor gene segments. Post hoc bulk sequencing allows for complementarity determining sequences to be mapped back to individual lymphocyte clones in super resolution images. In additional to its clinical applications in histopathology, these methods are also useful for the study of cellular and immunologic processes related to lymphoproliferative and autoimmune disorders.

CCR9 TARGETING MOIETY FOR THE TREATMENT OF CCR9-POSITIVE CANCER

Resumen de: US20260232732A1

The present invention provides therapeutics for the treatment of CCR9-positive cancers such as T-cell acute lymphoblastic leukemia. In particular, the present invention provides a CCR9 targeting moiety. The present invention furthermore relates to a CCR9 targeting moiety comprising a further targeting moiety, preferably a CD1a targeting moiety, a dual CAR comprising a CCR9 and a CD1a targeting moiety, their use in the treatment of CCR9 and/or CD1a positive cancers, and the use of a CCR9 targeting moiety and a separate CD1a targeting moiety for such treatment.

CIRCULAR RNA ENCODING CARS AND THE USE THEREOF

Resumen de: AU2024415673A1

Provided is a circular RNA encoding CARs and the use thereof to create immune cells that target specific diseases, e. g., lymphoma, multiple myeloma and leukemia and auntoimmune diseases, such as systemic lupus erythematousus, lupus nephritis and myasthenia gravis.

CRYSTALLINE FORMS OF N-4-4-(4-MORPHOLINYL)-7H-PYRROLO2,3-DPYRIMIDIN-6- YLPHENYL-4-3(R)-(L-OXO-2-PROPEN-L-YL)AMINO-L-PIPERIDINYLMETHYL-2-PYRIDINECARBOXAMIDE AS A COVALENT INHIBITOR OF MENIN-MLL INTERACTION

Resumen de: US20260232681A1

0000 Described herein is N-4-4-(4-morpholinyl)-7H-pyrrolo2,3-dpyrimidin-6-ylphenyl-4-3(R)-(1-oxo-2-propen-1-yl)amino-1-piperidinylmethyl-2-pyridinecarboxamide (Compound A) (Formula I), including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions or pharmaceutical formulations that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, diabetes, and inflammatory diseases or conditions. 0000

Keratin YK93-8, and Preparation Method Therefor, Pharmaceutical Composition Thereof and Use Thereof

Resumen de: US20260234207A1

0000 The present invention belongs to the field of biopharmaceuticals. Provided in the present invention are keratin YK93-8, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or a host cell having the nucleic acid molecule integrated into the genome, as well as a method for preparing keratin YK93-8 and a pharmaceutical composition of keratin YK93-8. Further provided is the use of the above-mentioned keratin YK93-8 and other products in the preparation of drugs, such as a drug for treating hyperplasia of prostate, lymphoma, melanoma, breast cancer, lung cancer and uterine myoma, an analgesic, a lactation drug and a coagulant.

Methods for Treating Multiple Myeloma

Resumen de: US20260234630A1

0000 Provided herein are methods of treating multiple myeloma, including multiple myeloma that is resistant to at least one therapeutic agent, comprising administering to a subject with multiple myeloma an inhibitor of Ubiquitin-Like with PHD and Ring Finger Domains 1 (UHRF1).

ANTIBODIES TO GLYCOSAMINOGLYCANS

Resumen de: US20260234243A1

0000 Polyspecific anti-glycosaminoglycan (GAG) antibodies and methods of use thereof for directly killing cancer cells. The anti-GAG antibodies can be used for purging cancer cells from autologous stem cell transplants (ASCT) or autologous bone marrow transplants (ABMT). The cancer cells may be multiple myeloma, Hodgkin's lymphoma, neuroblastoma, or any other cancer that expresses a membrane-tethered heparan sulfate proteoglycan (HSPG), such as syndecan or glypican.

METHODS OF TREATING LEUKEMIA OR LYMPHOMA

Resumen de: US20260232807A1

A method of impairing cancer cell growth in a mammal having leukemia or lymphoma is disclosed, the method including administering to the mammal a pharmaceutical composition comprising a pharmacologically active amount of (+)-BAY K8644 as a monotherapy or in combination with the tyrosine kinase inhibitor, Ibrutinib.

Low dose antibody-based methods for treating hematologic malignancies

Resumen de: US20260234248A1

0000 This invention provides a method for treating a subject afflicted with a hematologic malignancy comprising administering to the subject an agent targeting a hematologic malignancy-associated antigen, wherein the subject has a low peripheral cancerous cell burden. This invention also provides a method for treating a subject afflicted with a hematologic malignancy and having a high peripheral cancerous cell burden, comprising (i) medically lowering the subject's peripheral cancerous cell burden, and (ii) while the subject's peripheral cancerous cell burden is still low, administering to the subject an agent targeting a hematologic malignancy-associated antigen. Particularly envisioned are the subject methods for treating acute myeloid leukemia using an anti-CD33 antibody labeled with an alpha-emitting isotope, such as <225>Ac-HuM195.

MALT-1 INHIBITOR FOR TREATING GLIOMA

Resumen de: GR20250100041A

The present invention is directed to the field of personalized cancer care and treatment. In particular, a targeted approach is provided herein for treating neurological (e.g. brain) cancers (over)expressing mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), with inhibitors of dipeptidyl peptidase-4 (DPP-4), also known as gliptins. Further provided herein are in vitro diagnostic methods for determining an increased probability that a neurological cancer of a human subject will respond to the treatment with a gliptin, the methods comprising determination of MALT1 expression status and, optionally, of DPP-4 expression status in a sample obtained from the subject.

MALT-1 INHIBITOR FOR TREATING MULTIPLE MYELOMA

Resumen de: GR20250100042A

The present invention relates to a pharmaceutical composition comprising a compound selected from the group consisting of gliptins, pharmaceutically acceptable salts thereof and hydrates thereof for use in a therapeutic or prophylactic method of treating multiple myeloma disease in a human subject in need thereof. The method according to the present invention further relates to an oral administration of said pharmaceutical composition, wherein the method results in inhibition of intracellular MALTI activity, preferably inside myeloma cells. The present invention further relates to a therapeutic or prophylactic method of treating multiple myeloma and/or use of gliptins in the manufacture of a medicament for the therapeutic or prophylactic treatment of multiple myeloma.

USE OF TELOMERASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS AND MYELOPROLIFERATIVE NEOPLASMS

Nº publicación: EP4789716A2 12/08/2026

Solicitante:

GERON CORP [US]
Geron Corporation

Resumen de: EP4789716A2

0001 Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have myelodysplastic syndrome. Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having myelodysplastic syndrome.